Peter Grell MD· @GrellMd · X·· 14 hours agoScore70
Body
Phase 3 results from the INTerpath-001 trial confirm that the individualized mRNA vaccine plus pembrolizumab significantly improves outcomes in adjuvant treatment of malignant melanoma.
The era of mRNA vaccines in oncology has officially begun!👏
#ESMO26!
47 views · 1 like · 0 reposts · 0 replies
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: Peter Grell MD · x.com